BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32356416)

  • 1. Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B.
    Jung YW; Kim M; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    J Korean Med Sci; 2020 May; 35(17):e104. PubMed ID: 32356416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
    Lai CL; Ahn SH; Lee KS; Um SH; Cho M; Yoon SK; Lee JW; Park NH; Kweon YO; Sohn JH; Lee J; Kim JA; Han KH; Yuen MF
    Gut; 2014 Jun; 63(6):996-1004. PubMed ID: 23979965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
    Ahn SH; Kim W; Jung YK; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Yim HJ; Lee KS; Lim YS; Lee WS; Park NH; Jin SY; Kim KH; Choi W; Han KH
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1850-1859.e4. PubMed ID: 30448598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
    Yim HJ; Kim W; Ahn SH; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Jung YK; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Lee KS; Lim YS; Lee WS; Han KH
    Am J Gastroenterol; 2020 Aug; 115(8):1217-1225. PubMed ID: 32355123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
    Song DS; Kim W; Ahn SH; Yim HJ; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Jung YK; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Lee KS; Lim YS; Lee WS; Yang JM; Kim KH; Han KH; Um SH
    Clin Mol Hepatol; 2021 Apr; 27(2):346-359. PubMed ID: 33493393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.
    Yuen MF; Ahn SH; Lee KS; Um SH; Cho M; Yoon SK; Lee JW; Park NH; Kweon YO; Sohn JH; Lee J; Kim JA; Lai CL; Han KH
    J Hepatol; 2015 Mar; 62(3):526-32. PubMed ID: 25450709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
    Jung CY; Kim HW; Lee JI; Lee HW; Ahn SH; Kim SU; Kim BS
    Liver Int; 2022 Nov; 42(11):2408-2417. PubMed ID: 35943853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
    Yim HJ; Kim W; Ahn SH; Jung YK; Um SH; Sohn JH; Jang JY; Kim DJ; Park ES; Jin SY; Kim KH
    J Gastroenterol Hepatol; 2022 Feb; 37(2):378-386. PubMed ID: 34653281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    Wong GL; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Wong VW
    J Hepatol; 2018 Oct; 69(4):793-802. PubMed ID: 29758335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance.
    Sun Y; Wu K; Shen F; Qiu L; Chen B; Yu L; Chang S
    Minerva Med; 2017 Dec; 108(6):507-512. PubMed ID: 28889724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B.
    Kim TH; Kim JH; Yim HJ; Seo YS; Yim SY; Lee YS; Jung YK; Yeon JE; Um SH; Byun KS
    Gut Liver; 2024 Mar; 18(2):305-315. PubMed ID: 38213189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.
    Kim DS; Jeon MY; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    Clin Mol Hepatol; 2019 Sep; 25(3):283-293. PubMed ID: 30419649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years.
    Yalaki S; Yalcin MS
    Niger J Clin Pract; 2020 Feb; 23(2):226-231. PubMed ID: 32031098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Choi J; Kim GA; Han S; Lim YS
    Am J Gastroenterol; 2020 Mar; 115(3):406-414. PubMed ID: 31895708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B.
    Jin X; Chen YP; Yang YD; Li YM; Zheng L; Xu CQ
    PLoS One; 2012; 7(3):e34198. PubMed ID: 22479562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B.
    Song JE; Park JY
    Expert Opin Pharmacother; 2021 Dec; 22(18):2427-2433. PubMed ID: 34392744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy.
    Chang JW; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
    Gut Liver; 2021 Jan; 15(1):117-127. PubMed ID: 32066210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
    Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
    Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.